At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 45 enrolled
Drug / intervention
LRX712 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Placebo-controlled, Subject and Investigator Blinded Study Investigating the Safety, Tolerability and Preliminary Efficacy of 8-week Treatment With Intra-articular LRX712 to Regenerate Articular Cartilage in Patients With Mild/Moderate Knee Osteoarthritis
In Brief
A Phase 2 clinical trial evaluating LRX712 and Placebo for Osteoarthritis (OA). Completed, enrolled 45 participants across 1 site.
Detailed Summary
This study explored the preliminary efficacy of multiple intra-articular injections of LRX712 by evaluating the ability of the drug to restore structural integrity of articular cartilage. Efficacy was evaluated in the context of the systemic safety and local tolerability of the investigational drug.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis (OA)
CountriesNetherlands
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedSep 2019
Enrollment StartJul 2020
Primary CompletionAug 2024
Study CompletionJan 2025
TodayJul 2026
First PostedSep 20, 2019
Enrollment StartJul 20, 2020
Primary CompletionAug 8, 2024
Study CompletionJan 17, 2025
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 6.8 years ago
Interventions
LRX712drug
LRX712 intra-articular injections
Placeboother
Placebo intra-articular injections